ArticleClinical cardiology2026
Comparing Ferric Carboxymaltose Versus Iron Sucrose in Patients with Heart Failure.
Article in Clinical cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLimited evidence comparing different intravenous (IV) iron products is available to guide the optimal IV iron product in patients with heart failure (HF) and iron deficiency (IDef).
objectivesTo compare ferric carboxymaltose (FCM) with iron sucrose in patients with HF with reduced or mildly reduced ejection fraction.
methodsThis single-center retrospective cohort study included patients with HF with reduced or mildly reduced ejection fraction and IDef who received either FCM or iron sucrose. The primary outcome was IDef therapy goal achievement (defined as ferritin 100-300 mcg/L and iron saturation > 20%; ferritin > 300 mcg/L; or hemoglobin > 15 mg/dL regardless of iron study).
resultsA total of 78 patients in the FCM group and 21 in the iron sucrose group were included. The use of FCM was significantly associated with a higher rate of IDef treatment goal achievement after the induction course than iron sucrose (70.1 vs. 41.2%, p = 0.026). After adjusting for multiple variables, FCM use was significantly associated with a higher rate of the primary outcome than iron sucrose (adjusted OR 5.8 [95% CI 1.3-26.1], p = 0.022). No significant difference in adherence to the IV iron criteria was found between the two groups (80.8 vs. 81.0%, p = 0.985).
conclusionFerric carboxymaltose use was associated with a higher iron repletion rate than iron sucrose in patients with HF with reduced or mildly reduced ejection fraction and IDef.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.